Head-To-Head Analysis: Vapotherm (NYSE:VAPO) & Invivo Therapeutics (NYSE:NVIV) – TechNewsObserver

Vapotherm (NYSE:VAPO) and Invivo Therapeutics (NASDAQ:NVIV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Profitability

This table compares Vapotherm and Invivo Therapeutics net margins, return on equity and return on assets.

Institutional & Insider Ownership

60.0% of Vapotherm shares are owned by institutional investors. Comparatively, 7.0% of Invivo Therapeutics shares are owned by institutional investors. 34.4% of Vapotherm shares are owned by insiders. Comparatively, 0.3% of Invivo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Vapotherm and Invivo Therapeutics, as provided by MarketBeat.

Vapotherm presently has a consensus price target of $26.50, indicating a potential upside of 143.57%. Given Vapotherms higher probable upside, research analysts plainly believe Vapotherm is more favorable than Invivo Therapeutics.

Earnings & Valuation

This table compares Vapotherm and Invivo Therapeutics top-line revenue, earnings per share and valuation.

Invivo Therapeutics has lower revenue, but higher earnings than Vapotherm. Vapotherm is trading at a lower price-to-earnings ratio than Invivo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Vapotherm beats Invivo Therapeutics on 6 of the 11 factors compared between the two stocks.

About Vapotherm

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit and Q50 compressor; and disposable products comprising single-use disposables and nasal interfaces. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.

More:
Head-To-Head Analysis: Vapotherm (NYSE:VAPO) & Invivo Therapeutics (NYSE:NVIV) - TechNewsObserver